---
document_datetime: 2024-10-22 15:17:44
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bortezomib-fresenius-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: bortezomib-fresenius-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.1802564
conversion_datetime: 2025-12-15 19:38:58.639275
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Bortezomib Fresenius Kabi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                 |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010               | Renewal of the marketing authorisation. | 25/07/2024                          | 04/10/2024                                  | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Bortezomib Fresenius Kabi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0009           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                    | 06/02/2024   | 04/10/2024   | SmPC and PL     |                                                                                                                                          |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/424/2 02304 | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                | 30/11/2023   | n/a          |                 | PRAC Recommendation - maintenance                                                                                                        |
| IA/0007           | B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                     | 30/06/2023   | n/a          |                 |                                                                                                                                          |
| IA/0006           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                        | 13/04/2023   | n/a          |                 |                                                                                                                                          |
| IA/0005           | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                           | 28/07/2021   | 18/07/2022   | SmPC            | ATC code update                                                                                                                          |
| PSUSA/424/2 02004 | Periodic Safety Update EU Single assessment - bortezomib                                                                                                                                                                                                | 10/12/2020   | 18/02/2021   | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/424/202004. |
| IAIN/0004/G       | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- | 06/11/2020   | 18/02/2021   | Annex II and PL |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                  |            |            |                                  | an obsolete parameter)   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------|
| II/0001/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products | 23/07/2020 | 18/02/2021 | SmPC, Annex II, Labelling and PL |                          |
| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                   | 07/05/2020 | 18/02/2021 | Annex II                         |                          |